RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
CJC-1295 is an analogue of growth hormone-releasing hormone, or GHRH. Its foundational human studies examined an albumin-binding, long-acting compound that increased growth hormone and insulin-like growth factor 1, commonly called IGF-1. Those studies investigated hormone responses and persistence; they did not establish broad benefits for muscle growth, sleep, recovery, or aging. Their results also cannot be transferred to materials labeled CJC-1295 No DAC, which lack the defining albumin-binding modification. [1,2]
WHAT IS CJC-1295?
GHRH is a signaling hormone involved in the release of growth hormone from the pituitary. CJC-1295 was developed as a longer-acting analogue because the short persistence of natural GHRH limits its use as an experimental intervention. [1]
The compound described in the main clinical papers binds to albumin, a protein circulating in blood. This extends its presence in the body. The albumin-binding feature is commonly called Drug Affinity Complex, or DAC. [1,2]
A name on a vial is not sufficient to connect a material with these studies. The documented chemical identity must match the actual study compound.
WHAT DID THE INITIAL HUMAN TRIALS MEASURE?
A 2006 publication described two placebo-controlled trials lasting 28 and 49 days in healthy adults. CJC-1295 prolonged growth hormone and IGF-1 responses, with an estimated half-life of six to eight days. [1]
A half-life describes the decline in a compound's concentration; it is not a direct measure of how long a particular benefit lasts.
The research established biological activity in the hormone pathway. It did not demonstrate that the observed increases produced greater strength, faster injury recovery, improved sleep, or longer life. Those outcomes would require trials designed to measure them.
WERE NATURAL GROWTH HORMONE PULSES PRESERVED?
A separate 2006 study assessed overnight growth hormone patterns in healthy men before and one week after CJC-1295 exposure. Researchers collected repeated blood samples over 12 hours to distinguish pulse patterns from the background hormone level. [2]
Growth hormone remained pulsatile, but the reported frequency and magnitude of secretory pulses were not significantly altered. Instead, the background or trough level increased, contributing to higher average growth hormone and IGF-1. [2]
This distinction matters. Preserved pulsatility does not mean the full hormone pattern was unchanged, and it does not prove the intervention is physiologically harmless. The study describes how secretion changed within a specific observation window.
WHY CAN THESE FINDINGS NOT BE APPLIED TO NO DAC MATERIALS?
The prolonged persistence in these papers was linked to albumin binding. A material without that feature is not the same intervention. It should not inherit the reported multi-day half-life or prolonged hormone response simply because its name includes CJC-1295.
Comparisons should therefore specify the exact structure, rather than grouping DAC and No DAC materials together. A study of one cannot establish the pharmacokinetics, activity, or safety of the other.
WHAT REMAINS UNCERTAIN?
The principal human studies discussed here were short and involved healthy volunteers. They do not establish long-term clinical benefits, uncommon adverse effects, or results in populations outside those studied. A favorable short-term observation also cannot rule out effects that were not measured.
For laboratory research, hormone-response findings are useful when the scientific question concerns that pathway. They should not become general claims about health or performance. Published studies also do not verify the identity, purity, stability, or biological activity of a separately supplied material; those properties need material-specific documentation and testing.
REFERENCES
[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799–805.
https://doi.org/10.1210/jc.2005-1536
[2] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792–4797.
https://doi.org/10.1210/jc.2006-1702